vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $19.12 and traded as low as $16.61. vTv Therapeutics shares last traded at $16.10, with a volume of 716 shares changing hands.
Analyst Ratings Changes
VTVT has been the subject of a number of recent research reports. HC Wainwright assumed coverage on vTv Therapeutics in a research report on Wednesday, April 9th. They issued a "buy" rating and a $36.00 target price for the company. Wall Street Zen began coverage on vTv Therapeutics in a research note on Wednesday, April 16th. They set a "sell" rating for the company.
View Our Latest Stock Report on VTVT
vTv Therapeutics Stock Up 1.8%
The firm has a 50-day simple moving average of $19.12 and a 200-day simple moving average of $17.26. The stock has a market cap of $54.04 million, a PE ratio of -3.73 and a beta of 0.59.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.04).
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. bought a new stake in vTv Therapeutics during the fourth quarter valued at $25,000. Geode Capital Management LLC raised its holdings in shares of vTv Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock valued at $158,000 after acquiring an additional 1,327 shares in the last quarter. Finally, Connective Capital Management LLC purchased a new stake in shares of vTv Therapeutics in the 1st quarter valued at about $162,000. 17.51% of the stock is currently owned by hedge funds and other institutional investors.
vTv Therapeutics Company Profile
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
See Also
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
